OBJECTIVE: Among causes for congenital heart disease (CHD) chromosomal abnormalities account for approximately 20%. We aimed to evaluate the utility of chromosomal microarray as the first tier test for chromosomal abnormalities in fetuses with CHD and to identify different types of chromosomal abnormalities association to CHD subgroups. STUDY DESIGN: This is a retrospective data from 336 pregnancies diagnosed with CHD between 2011 and 2016 were reviewed. Total of 209 prenatal cases of CHD were investigated using single nucleotide polymorphism (SNP) during the study period. After complete analysis, cohort was divided into two groups, isolated CHD and nonisolated CHD (fetuses with extracardiac anomalies). Classification of chromosomal abnormalities were done based on American college of genetics guidelines into numerical chromosomal abnormalities (NCA) which included aneuploidies and partial aneuploidies, and copy number variants (CNV) which for the purposes of this study was further classified into pathogenic CNV (DiGeorge, other), and variable of unknown significance (VUS) or likely benign. RESULTS: Pathogenic chromosomal abnormalities were identified in 43.8% (n¼92), with 69.5% (n¼64) of them being numerical abnormalities, and 15.2% (n¼14) being pathogenic CNV. The detection rate for VUS or likely benign was 15.2% (n¼14). Pathogenic chromosomal abnormalities (NCA and pathogenic CNV) were 22.1% (n¼32) in the isolated CHD group, and 70.8% (n¼46) in the non-isolated CHD group (P< 0.0001).
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Subgroup analysis of different types of CHD was also conducted by dividing the cohort into 8 groups (see table) . Overall atrioventricular septal defects (AVSD) were the most common to be associated with chromosomal abnormalities (31.5%) followed by conotruncal defects 29.3%. Pathogenic CNV were most common in conotruncal defects group (10.8%) CONCLUSION: Our study demonstrates SNP array is a reliable and high resolution method and should be used as first tier test for all fetuses with CHD in clinical practice, regardless of the types of CHD or whether combined with extracardiac defects or not.
67 Renal artery doppler studies in monochorionic, diamniotic twin pregnancies with and without twintwin transfusion syndrome OBJECTIVE: To evaluate and compare renal artery Doppler (RAD) parameters in monochorionic, diamniotic (MCDA) twin pregnancies with and without twin-twin transfusion syndrome (TTTS). STUDY DESIGN: We conducted a prospective study of women with MCDA twin pregnancies complicated by TTTS and women with gestational-age matched MCDA twin pregnancies without TTTS. For each twin, RAD assessment was performed from a coronal view of the fetus to measure pulsatility index (PI), resistive index (RI), and peak systolic velocity (PSV). We compared each measurement between donors and controls, and recipients and controls. Inter-twin ratios of the PI, RI, and PSV were compared between TTTS cases and MCDA controls. Lastly, we performed a subgroup analysis involving pregnancies with TTTS that underwent fetoscopic laser therapy and resulted in twin survivors in order to evaluate if laser therapy influenced RAD findings. RESULTS: We recruited 12 cases and 12 controls. Between TTTS donors and controls, there was no difference in RAD PI (median ¼ 1.27 [1.14- .002. Applying a RAD PSV ratio cut-off of greater than 1.35 for the diagnosis of TTTS, 11/12 cases with TTTS and all 12/12 controls without TTTS were correctly classified (92% sensitivity, 100% specificity). Among TTTS cases with double survivors after undergoing laser therapy (n¼4), pre-laser RAD PSV ratios (M¼1.46, SD¼0.37) were higher than post-laser RAD PSV ratios (M¼0.87, SD¼0.37), p¼0.02. Post-laser inter-twin RAD PSV ratios were similar to those among matched control twin pairs, p¼0.125. CONCLUSION: RAD PSV ratios differed between MCDA twins complicated by TTTS and those without TTTS. This effect was driven by altered donor twin RAD PSV values. Laser therapy may normalize RAD PSV ratios and donor twin RAD values to those observed in MCDA twins without TTTS. Further study should explore the utility of RAD PSV as a tool for TTTS prediction, diagnosis, staging, as well as for the evaluation of fetal response to laser therapy.
